FABP1 ‐Mediated Lipid Metabolic Reprogramming Buffers Lipotoxicity in Nephrolithiasis via Maintaining PPARγ Activity
- 18 September 2026
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 40 (18) , e72320
Abstract
Nephrolithiasis‐induced lipotoxicity is a critical driver of tubular cell death and renal function decline, yet targeted pharmacological interventions remain a major unmet clinical need. While Fatty Acid‐Binding Protein 1 (FABP1) is widely recognized as a passive injury biomarker, its active functional role in buffering lipotoxicity during nephrolithiasis remains uncharacterized. By integrating clinical specimens from nephrolithiasis patients, AAV9‐mediated kidney‐specific Fabp1 knockdown murine models, and HK‐2 cell lines, we delineated the FABP1 regulatory landscape using transcriptomic and untargeted metabolomic profiling. Furthermore, the core mechanistic interactions were definitively validated via Co‐Immunoprecipitation (Co‐IP) and PPRE‐driven dual‐luciferase reporter assays. FABP1 is significantly upregulated in nephrolithiasis. Mechanistically, crystal‐induced lysosomal stress triggers Ca 2+ efflux, which activates the calcineurin pathway to drive TFEB nuclear translocation and subsequent FABP1 transcription. Crucially, FABP1 functions as an indispensable nuclear chaperone, physically engaging PPARγ to sustain its core transcriptional activity. FABP1 deficiency dismantles this defense, impairing protective lipid droplet biogenesis to sequester free fatty acids. This failure precipitates excessive 4‐HNE accumulation, marked lipid peroxidation, TCA cycle collapse, a pronounced NF‐κB‐driven inflammatory storm, and ultimate renal functional deterioration. Importantly, targeted pharmacological activation of PPARγ utilizing rosiglitazone circumvents FABP1 depletion, rewiring global lipid and energetic fluxes to rescue tubular cell injury. Our findings redefine FABP1 from a passive clinical biomarker to an active homeostatic buffer. This study delineates the Ca 2+ /calcineurin‐TFEB‐FABP1‐PPARγ axis as a vital defense mechanism against lipotoxicity, providing a compelling translational rationale for PPARγ‐targeted metabolic interventions to treat nephrolithiasis.Keywords
Funding Information
- National Natural Science Foundation of China (82070724)
- National Natural Science Foundation of China (82370768)
This publication has 47 references indexed in Scilit:
- Network of cell death in myocardial ischemia-reperfusion injury: mechanisms and targeted therapeutic strategiesBiochemical Pharmacology, 2026
- Depalmitoylation of TEAD1 facilitates lipid droplet accumulation and resistance to oxidative stress by transactivating PP2AcαFree Radical Biology and Medicine, 2025
- Knockdown of long non-coding RNA SBF2-AS1 inhibits calcium oxalate-induced HK-2 cell injury by regulating the miR-302e/NLRP3 pathwayUrolithiasis, 2024
- Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practiceCell Stress and Chaperones, 2020
- Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver diseaseFEBS Open Bio, 2017
- Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney DiseaseKidney International Reports, 2017
- Proinflammatory and Metabolic Changes Facilitate Renal Crystal Deposition in an Obese Mouse Model of Metabolic SyndromeJournal of Urology, 2015
- Antioxidant Role for Lipid Droplets in a Stem Cell Niche of DrosophilaCell, 2015
- L-FABP: A novel biomarker of kidney diseaseClinica Chimica Acta, 2015
- Experimental Induction of Calcium Oxalate Nephrolithiasis in MiceJournal of Urology, 2010